obesity
Nestlé’s baby food products sold in low and middle-income countries contain unhealthy levels of sugar, found an investigation by Swiss NGO Public Eye and the International Baby Food Action Network (IBFAN). What’s more, while the food giant abides by marketing restrictions in Europe, it also “takes advantage of the weakness of existing regulations” in lower and mid-income countries, the probe found. Researchers examined about 150 products and found in many cases that the same baby formula with no added sugar in Switzerland, Germany, France, and the UK, contained unhealthy levels of it in countr...
Euronews (English)
Scientists say stroke, diabetic nerve damage, and dementia are making neurological diseases the biggest cause of ill health globally. According to a recent study00038-3/fulltext#%20) published in the journal Lancet Neurology, researchers from the University of Washington in the US and their international collaborators say neurological conditions now affect 3.4 billion people worldwide. The global counts for total nervous system health loss have increased by 18.2 per cent from 375 million in 1990 to 443 million disability-adjusted life years (DALYs) in 2021. Meet 'Viv,' the AI companion helping...
Euronews (English)
Danish pharmaceutical powerhouse Novo Nordisk has emerged as one of the standout performers among European mega-cap stocks in the early months of this year, boasting a robust 25% surge year to date. This performance further cemented Novo Nordisk's status as the largest European company by market capitalisation, reaching almost €550 billion and outpacing the market value of Tesla. Over the past year, the Danish pharma titan has seen its price jump by 80%, a rate of increase unmatched by any other European company valued at €100 billion or more. Novo Nordisk's growth driver: Weight-loss drug Weg...
Euronews (English)
Washington (AFP) - The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage. Wegovy, produced by Danish pharmaceutical giant Novo Nordisk, was approved "to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight," the FDA said in a statement. The FDA's decision could be a game changer for the approximately 70 percent of American adults who it says are either obese or ...
AFP
Pharmaceutical giant Novo Nordisk has recently overtaken electric vehicle maker Tesla, in terms of market valuation, following upbeat initial trial data for a new obesity drug. Novo Nordisk, already well known for the popular obesity drug Wegovy, had a market valuation of about $566 billion (€517.6 billion), on Thursday, as shares rose about 8%. That is more than companies such as Tesla and Visa, according to London Stock Exchange Group (LSEG) data. It also surpassed LVMH as Europe's biggest company in terms of market valuation last year. Following the launch of Wegovy in June 2021, Novo Nordi...
Euronews (English)
More than one billion people in the world are now living with obesity, a new study published in The Lancet has found. Obesity, defined by a body mass index (BMI) equal to or exceeding 30 for adults, has become the main form of malnutrition in numerous countries. The prevalence of obesity has risen twice as rapidly among children and adolescents globally compared to adults. The study analysed the weight and height measurements of over 220 million people across 200 countries between 1990 to 2022. In 2022, the findings pointed to an estimated 879 million adults living with obesity - 504 million w...
Euronews (English)
Washington (AFP) - Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity. "I would work out sometimes three times a day, I was doing hours worth of classes. I was eating really, really clean… and nothing was changing" the 36-year-old esthetician told AFP in a recent interview. "I heard about Ozempic for a while and then you start to see other people doing it like celebrities and then dropping weight super fast," she said. Fearing gastrointestinal iss...
AFP
Washington (AFP) - The US Food and Drug Administration (FDA) on Wednesday announced it had approved Eli Lilly's highly anticipated weight loss drug Zepbound, the latest entrant in a field of powerful -- and lucrative -- new obesity medicines. It is expected to be available in the United States within weeks, joining the likes of Novo Nordisk's successful Ozempic and Wegovy, and is widely expected to become a bestseller. JPMorgan analysts have predicted annual sales for so-called GLP-1 drugs to reach $140 billion by 2032, with the market dominated by Novo and Lilly. Administered by weekly injec...
AFP
Washington (AFP) - Drugs like Ozempic, which have become increasingly popular for losing weight, heighten the risk of certain severe gastrointestinal problems including stomach paralysis, according to a large study published Thursday. The paper, published in the Journal of the American Medical Association (JAMA), looked at a class of drugs called GLP-1 agonists that includes the brands Wegovy, Ozempic, Rybelsus and Saxenda. It then compared the rate of serious side effects to another class of weight loss drug, bupropion-naltrexone. The GLP-1 agonists were associated with an almost four times ...
AFP
Pediatricians Can Be Sued Under New Obesity Guidelines; They Set Legal Standard For Reasonable Care Of Overweight Children Pediatricians Can Be SuedQ4 2022 hedge fund letters, conferences and more He has also been called "The Law Professor Who Masterminded Litigation Against the Tobacco Industry," a "King of Class Action Lawsuits," and "a Driving Force Behind the Lawsuits That Have Cost Tobacco Companies Billions of Dollars." The official "Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity," issued by the American Academy of Pediatrics [APA], ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら